American College of Cardiology/American Heart Association (ACC/AHA) Class I Guidelines for the Treatment of Cholesterol to Reduce Atherosclerotic Cardiovascular Risk: Implications for US Hispanics/Latinos Based on Findings From the Hispanic Community Health Study/Study of Latinos (HCHS/SOL)

Journal of the American Heart Association
Waqas T QureshiCarlos J Rodriguez

Abstract

The prevalence estimates of statin eligibility among Hispanic/Latinos living in the United States under the new 2013 American College of Cardiology/American Heart Association (ACC/AHA) cholesterol treatment guidelines are not known. We estimated prevalence of statin eligibility under 2013 ACC/AHA and 3rd National Cholesterol Education Program Adult Treatment Panel (NCEP/ATP III) guidelines among Hispanic Community Health Study/Study of Latinos (n=16 415; mean age 41 years, 40% males) by using sampling weights calibrated to the 2010 US census. We examined the characteristics of Hispanic/Latinos treated and not treated with statins under both guidelines. We also redetermined the statin-therapy eligibility by using black risk estimates for Dominicans, Cubans, Puerto Ricans, and Central Americans. Compared with NCEP/ATP III guidelines, statin eligibility increased from 15.9% (95% CI 15.0-16.7%) to 26.9% (95% CI 25.7-28.0%) under the 2013 ACC/AHA guidelines. This was mainly driven by the ≥7.5% atherosclerotic cardiovascular disease risk criteria (prevalence 13.9% [95% CI 13.0-14.7%]). Of the participants eligible for statin eligibility under NCEP/ATP III and ACC/AHA guidelines, only 28.2% (95% CI 26.3-30.0%) and 20.6% (95% CI 19.4-2...Continue Reading

References

May 26, 1998·JAMA : the Journal of the American Medical Association·J AvornJ LeLorier
Jul 23, 2002·JAMA : the Journal of the American Medical Association·Cynthia A JackeviciusJack V Tu
Jul 23, 2002·JAMA : the Journal of the American Medical Association·William B Applegate
Dec 29, 2005·American Journal of Public Health·David P Smith, Benjamin S Bradshaw
Jul 9, 2010·Annals of Epidemiology·Paul D SorlieGerardo Heiss
Jul 9, 2010·Annals of Epidemiology·Lisa M LavangeJohn P Elder
Mar 19, 2011·The American Journal of Cardiology·Alexander KulikNiteesh K Choudhry
Apr 13, 2012·American Journal of Public Health·Luisa N Borrell, Elizabeth A Lancet
Nov 3, 2012·JAMA : the Journal of the American Medical Association·Martha L DaviglusJeremiah Stamler
Jan 19, 2013·American Journal of Public Health·John M RuizTimothy B Smith
Oct 8, 2013·European Journal of Internal Medicine·Mery Cortes-BergoderiFrancisco Lopez-Jimenez
Nov 14, 2013·Journal of the American Pharmacists Association : JAPhA
Mar 22, 2014·The New England Journal of Medicine·Michael J PencinaEric D Peterson
Sep 10, 2014·The American Journal of Medicine·Carlos J RodriguezRobert C Kaplan
Jul 15, 2015·JAMA : the Journal of the American Medical Association·Amit PursnaniUdo Hoffmann
Feb 20, 2016·Journal of Clinical Lipidology·Guadalupe EcheverríaAttilio Rigotti
May 7, 2016·Journal of the American College of Cardiology·Jamal S RanaAlan S Go
May 7, 2016·Journal of the American College of Cardiology·Michael J Blaha

❮ Previous
Next ❯

Citations

Feb 1, 2019·Circulation·Emelia J BenjaminUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Apr 26, 2019·Journal of the American Heart Association·Alanna M ChamberlainRhonda M Cooper-DeHoff
Jul 6, 2019·Journal of Community Health·Maria E Rodriguez-AlcaláStephen Jeanetta
Jan 30, 2020·Circulation·Salim S ViraniUNKNOWN American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee
Mar 2, 2021·Journal of Managed Care & Specialty Pharmacy·José J Hernández-MuñozChandni R Kamdar
Jul 31, 2021·American Journal of Preventive Cardiology·Harold E BaysPeter P Toth

❮ Previous
Next ❯

Methods Mentioned

BETA
blood draws
coronary bypass

Related Concepts

Related Feeds

Cardiovascular Disease Pathophysiology

Cardiovascular disease involves several different processes that contribute to the pathological mechanism, including hyperglycemia, inflammation, atherosclerosis, hypertension and more. Vasculature stability plays a critical role in the development of the disease. Discover the latest research on cardiovascular disease pathophysiology here.

Atherosclerosis Disease Progression

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Related Papers

© 2022 Meta ULC. All rights reserved